"New Jersey's biopharmaceutical and medical technology community has faced significant challenges over the past year--some of which are endemic solely to our industry, others of which affect the broader business community as a whole," said HINJ president Bob Franks.
"This average compensation figure is commensurate with the high skill and education levels of biopharmaceutical and medical technology personnel, and is largely consistent with HINJ member companies surveyed," said Mr.
In 2008, HINJ member companies participating in the survey invested approximately $7.5 billion in R&D activity.
In the medical technology field, 12 new product applications (PMAs) are currently on file with the FDA by HINJ member companies.
R&D workers, along with others employed in the industry, are also active consumers, according to the HINJ survey.
And HINJ member companies' economic impact generated $17.2 billion in NJ business sales.
According to the HINJ survey, the industry has again shown itself to be a leader in capital construction investment.
Estimated worldwide giving by HINJ member companies was approximately $4.5 billion in 2008, with $221 million directly benefitting New Jersey causes.
Dean Paranicas, HINJ
president and chief executive officer, said: "HINJ
is pleased to join with the New Jersey Realtors, the Partnership for a Drug-Free New Jersey and PhRMA on this innovative initiative to educate the public on the importance of securing medicine in the household.